We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to a better life by preventing and treating serious kidney diseases. ROSgard, our biological drug candidate, mimics the body’s own powerful defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents kidney damage by protecting, cleaning and repairing the exposed cells and tissues.

Our early clinical program consists of two phase I studies on healthy subjects and one phase Ib study on patients undergoing open-heart surgery.

Read more

CLINICAL STUDIES

ROSgard, our drug candidate, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more

ROSgard™

Acute kidney injury is a large market. The estimated annual value is USD 6.3 bn in the USA and GBP 500 mn in the UK.

Read more

INVESTOR RELATIONS

Press releases
  • 08 Jul 2020  ·  Regulatory information

    Guard Therapeutics presents positive follow-up analysis from phase 1 study of ROSgard

    Read more
  • 06 Jul 2020  ·  Regulatory information

    Guard Therapeutics appoints Peter Gilmour as Head of Preclinical Science

    Read more
  • 17 Mar 2020

    Guard Therapeutics announces positive top line results from a clinical phase 1a study of ROSgard

    Read more
Show more
Calendar & reports
News, reports & presentations
  • 04 Jun 2020 / Analysis

    Monocl valuation report for cardiac surgery AKI 2018

    Read more
  • 04 Jun 2020 / Analysis

    Redeye valuation report 2019

    Read more